Submission of supplemental New Drug Application (sNDA) to the U.S F.D.A was based on data from the Phase III PRIMA study on niraparib as maintenance treatment for ovarian cancer patients.
from Medindia Health News https://ift.tt/32x7fW7
No comments:
Post a Comment